Endothelins as a Potential Target for Anticancer Therapy

10.29685/JCM.200902.0001

Deimante Tamkus；Anas Ai-Janadi；Gregory Fink；Ganapathy Krishnan；Nikolay V. Dimitrov

endothelin ； angiogenesis ； apoptosis ； atrasentan ； HIF-1α

Journal of Cancer Molecules

4卷6期（2009 / 02 / 28）

163 - 167

英文

The endothelin (ET) system consists of three small peptides (ET-1, ET-2, ET-3) and two ET receptors (ET(subscript A) and ET(subscript B)). ETs play key physiologic roles in normal tissue, acting as modulators of vasomotor tone, tissue differentiation, cell proliferation, and hormone production. Besides their physiologic roles, endothelins are implicated in pathologic conditions, such as vascular diseases and cancer. ET system is differentially expressed in invasive cancer compared to precancerous lesions and their normal tissue counterparts. In tumors, ETs exhibit antiapoptotic and angiogenic activities which facilitate malignant growth. Increased ET-1 production and ET(subscript A) receptor density keeps tumor vessels in vasoconstrictive state, leading to decreased perfusion, hypoxia and resistance to radiotherapy and chemotherapy. In this article, the potential of ETs as a target for anticancer therapy and novel therapeutic strategies are discussed.